News Digest / Ticker: ANIX

Ticker: ANIX

05:05pm, Wednesday, Sep 10, 2025

Anixa cuts costs, $16M cash as CAR‑T and vaccine Phase 1 trials advance; pre‑revenue

Anixa Biosciences, Inc. (NASDAQ: ANIX) Quick take: Anixa remains a pre-revenue biotech advancing cancer vaccines and a CAR‑T therapeutic. The company cut operating spending versus prior periods and retains roughly $16.0M in cash and short‑term investments, but continues to report operating losses...

05:02pm, Wednesday, May 28, 2025

Anixa Biosciences Reports Q2 2025 Results: No Revenue, Reduced Losses Amid Ongoing Trials

05:01pm, Tuesday, Mar 11, 2025

Anixa Biosciences Reports Mixed Q1 2025 Results Amid Ongoing Revenue Challenges and Cost Management